Form 4: Monopar Therapeutics CEO Chandler Robinson Reports Stock Transactions
SEC Form 4 Filing
Chandler Robinson, CEO of Monopar Therapeutics, reports the vesting and settlement of restricted stock units, resulting in the acquisition and disposal of common stock.
Summary
- On March 31, 2025, Chandler Robinson, the CEO of Monopar Therapeutics, reported transactions involving common stock.
- These transactions involved the vesting and settlement of restricted stock units (RSUs).
- 4,106 shares were acquired upon the vesting of RSUs.
- 1,204 shares were withheld by the issuer to cover withholding taxes related to the vesting of the RSUs at a price of $36.41.
- Following these transactions, Robinson directly owns 65,993 shares of common stock.
- Robinson may be deemed to share voting and dispositive power over 855,589 shares held by Tactic Pharma LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.
- Robinson directly owns 94,669 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating neutral sentiment as it reports routine stock transactions related to executive compensation.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry as part of executive compensation packages.
Comparison to Industry Standards
- Stock-based compensation is a common practice in the biotech and pharmaceutical industries to align executive interests with shareholder value.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize restricted stock units as part of their executive compensation packages.
- The vesting schedules and terms of these RSUs are generally comparable to industry standards, with vesting occurring over a multi-year period.
Stakeholder Impact
- The vesting of restricted stock units can have a minor dilutive effect on existing shareholders.
- Executive compensation is always of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| February 2, 2022 | Reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. |
| February 1, 2023 | Reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. |
| 03/31/2025 | Date of the reported stock transactions, including the vesting of restricted stock units and withholding of shares for taxes. |
| 04/02/2025 | Date of signature for the Form 4 filing. |
| December 31, 2025 | Date when the restricted stock units granted on February 2, 2022 are fully vested. |
| December 31, 2026 | Date when the restricted stock units granted on February 1, 2023 are fully vested. |
Keywords
Monopar Therapeutics, Chandler Robinson, MNPR, Form 4, SEC Filing, Stock Transaction, Restricted Stock Units, RSU, Beneficial Ownership, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.